In final days at Merck, Roger Perlmutter bets big on a little-known Covid-19 treatment
Roger Perlmutter is spending his last days at Merck, well, spending.
Two weeks after snapping up the antibody-drug conjugate biotech VelosBio for $2.75 billion …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
